For the quarter ending 2025-09-30, VTYX made $26,977K in revenue. -$22,854K in net income. Net profit margin of -84.72%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development (includes related party amounts of 255, 249, 756 and 752, respectively) | 17,706 | 22,266 | ||
| General and administrative | 7,168 | 7,067 | ||
| Total operating expenses | 24,874 | 29,333 | ||
| Loss from operations | -24,874 | -29,333 | ||
| Interest income | 2,055 | 2,367 | ||
| Other expense | -10 | -21 | ||
| Total other (income) expense | 2,045 | 2,346 | ||
| Net loss | -22,829 | -26,987 | ||
| Unrealized gain (loss) on marketable securities | 48 | -152 | ||
| Foreign currency translation | -73 | 246 | ||
| Comprehensive loss | -22,854 | -26,893 | ||
| Basic net loss per share attributable to common shareholders | -0.32 | -0.38 | ||
| Diluted net loss per share attributable to common shareholders | -0.32 | -0.38 | ||
| Weighted average shares of common stock outstanding, basic | 71,304,084 | 71,198,652 | ||
| Weighted average shares of common stock outstanding, diluted | 71,304,084 | 71,198,652 | ||
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc. (VTYX)